Lukasz Kwinta

Krakow, MA 31501, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal.

Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal.

Journal: Cancers

Published: July 19, 2026

Adverse Events as a Surrogate of Sufficient Pharmacological Exposure in Metronomic Combination Chemotherapy: Extended Real-World Cohort Analysis of the FulVEC Regimen in Metastatic ER+/HER2- Breast Cancer.

Adverse Events as a Surrogate of Sufficient Pharmacological Exposure in Metronomic Combination Chemotherapy: Extended Real-World Cohort Analysis of the FulVEC Regimen in Metastatic ER+/HER2- Breast Cancer.

Journal: Cancers

Published: June 12, 2026

Pretreatment NPLH as a Potential Predictor of Pathologic Complete Response to Accelerated MVAC Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Comparison with NLR and PLR.

Pretreatment NPLH as a Potential Predictor of Pathologic Complete Response to Accelerated MVAC Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Comparison with NLR and PLR.

Journal: Cancers

Published: May 21, 2026

Neoadjuvant Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy for Muscle-Invasive Urothelial Cancer: Large, Single-Center Analysis of Consecutive Patients' Data.

Neoadjuvant Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy for Muscle-Invasive Urothelial Cancer: Large, Single-Center Analysis of Consecutive Patients' Data.

Journal: Cancers

Published: December 30, 2024

The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting-A Nation-Wide Retrospective Analysis (RACER).

The Impact of Sidedness on the Efficacy of Anti-EGFR-Based First-Line Chemotherapy in Advanced Colorectal Cancer Patients in Real-Life Setting-A Nation-Wide Retrospective Analysis (RACER).

Journal: Cancers

Published: July 27, 2023

Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study.

Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study.

Journal: International journal of molecular sciences

Published: April 23, 2023

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer.

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer.

Journal: Cancers

Published: December 29, 2022

Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer-A Retrospective Analysis of Consecutive Patients Data.

Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer-A Retrospective Analysis of Consecutive Patients Data.

Journal: Journal of clinical medicine

Published: December 23, 2022

Reduction of Cancer-Induced Thrombocytosis as a Biomarker of Improved Outcomes in Advanced Gastric Cancer.

Reduction of Cancer-Induced Thrombocytosis as a Biomarker of Improved Outcomes in Advanced Gastric Cancer.

Journal: Journal of clinical medicine

Published: February 08, 2022

Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients.

Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients.

Journal: Journal of clinical medicine

Published: July 28, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026